News >

No Survival Benefit With Abemaciclib in KRAS+ NSCLC

Jason Harris
Published: Tuesday, Oct 10, 2017

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD
In topline results from the phase III JUNIPER trial, abemaciclib (Verzenio) failed to meet its primary endpoint of improving overall survival (OS) versus erlotinib (Tarceva) in patients with KRAS-mutated, advanced non–small cell lung cancer (NSCLC) who progressed after platinum-based chemotherapy.

However, the drug showed activity in an analysis of the secondary endpoints of progression-free survival (PFS) and overall response rate (ORR), according Lilly Oncology, the manufacturer of the CDK4/6 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication